Technological advancements, rise in prevalence of cancer, and increase in genome mapping programs and number of R&D activities drive the growth of the global epigenetics market.
the global Epigenetics Market was pegged at $771.9 million in 2019, and is projected to reach $2.16 billion by 2027, growing at a CAGR of 13.6% from 2020 to 2027.
The kits segment held the lion's share
By product, the kits segment held the largest share in 2019, accounting for nearly two-fifths of the global epigenetics market, owing to increase in the aging population, rise in incidences of chronic diseases, and growth in adoption of epigenetic procedures. However, the instruments segment is expected to register the highest CAGR of 15.5% during the forecast period, due to surge in research, innovation, & development across different laboratory settings.
The academic and research institutes segment to register the highest CAGR through 2027
By end user, the academic and research institutes segment is anticipated to manifest the highest CAGR of 14.5% from 2020 to 2027, as high-throughput and massive parallelization of next-generation sequencing have influenced researchers to sequence entire genomes of different organisms, ranging from humans to microorganisms. However, the pharmaceutical and biotechnology companies segment contributed the largest share in 2019, holding more than half of the global epigenetics market, as these companies have invested in epigenetic research to understand the complex pattern of drug resistance developed by microorganisms, oncology, molecular aspects of cancer, and drug discovery.
Major market players
- Abcam Plc.
- Agilent Technologies, Inc.
- Active Motif, Inc.
- Illumina Inc.
- Diagenode, PerkinElmer, Inc.
- Merck Millipore
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Zymo Research
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/846